Characterization of pathologic complete response to neoadjuvant chemotherapy among breast cancer patients in the National Cancer Database
Open Access
Abstract
No abstract availableKeywords
Funding Information
- School of Medicine, Washington University in St. Louis
- National Cancer Institute
- Alvin J. Siteman Cancer Center
This publication has 23 references indexed in Scilit:
- Tailoring treatment to cancer risk and patient preference: the 2025 St Gallen International Breast Cancer Consensus Statement on individualizing therapy for patients with early breast cancerAnnals of Oncology, 2025
- Clinicopathological response to neoadjuvant therapies and pathological complete response as a biomarker of survival in human epidermal growth factor receptor-2 enriched breast cancer – A retrospective cohort studyThe Breast, 2021
- Complete pathologic response rate to neoadjuvant chemotherapy increases with increasing HER2/CEP17 ratio in HER2 overexpressing breast cancer: analysis of the National Cancer Database (NCDB)Breast Cancer Research and Treatment, 2020
- Nodal Response to Neoadjuvant Chemotherapy Predicts Receipt of Radiation Therapy After Breast Cancer DiagnosisInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2020
- Characterizing Response to Neoadjuvant Chemotherapy in Invasive Lobular Breast CarcinomaJournal of Surgical Research, 2019
- Race is associated with completion of neoadjuvant chemotherapy for breast cancerSurgery, 2018
- Race, response to chemotherapy, and outcome within clinical breast cancer subtypesBreast Cancer Research and Treatment, 2015
- Cancer survival disparities by health insurance statusCancer Medicine, 2013
- Cancer Survival in Kentucky and Health Insurance CoverageArchives of internal medicine (1960), 2003
- Effects of health insurance and race on breast carcinoma treatments and outcomesCancer, 2000